Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2018, Article ID 8289253, 16 pages
https://doi.org/10.1155/2018/8289253
Review Article

Pharmacological Management of Diabetic Macular Edema in Real-Life Observational Studies

1Department of Ophthalmology, Croix-Rousse University Hospital, Hospices Civils de Lyon, University of Lyon I, 69004 Lyon, France
2CNRS UMR 5510 Mateis, 69621 Villeurbanne, France

Correspondence should be addressed to Laurent Kodjikian; rf.oodanaw@tnerual.naikijdok

Received 30 March 2018; Revised 15 June 2018; Accepted 5 August 2018; Published 28 August 2018

Academic Editor: Valentin Huerva

Copyright © 2018 Laurent Kodjikian et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M. D. Abràmoff, Y. Lou, A. Erginay et al., “Improved automated detection of diabetic retinopathy on a publicly available dataset through integration of deep learning,” Investigative Ophthalmology & Visual Science, vol. 57, no. 13, pp. 5200–5206, 2016. View at Publisher · View at Google Scholar · View at Scopus
  2. N. M. Holekamp, “Overview of diabetic macular edema,” The American Journal of Managed Care, 10, pp. 284–291, 2016. View at Google Scholar
  3. R. Klein, B. E. K. Klein, S. E. Moss, M. D. Davis, and D. L. DeMets, “The Wisconsin epidemiologic study of diabetic retinopathy. IV. Diabetic macular edema,” Ophthalmology, vol. 91, no. 12, pp. 1464–1474, 1984. View at Publisher · View at Google Scholar · View at Scopus
  4. K. Gu, C. C. Cowie, and M. I. Harris, “Mortality in adults with and without diabetes in a national cohort of the U.S. population, 1971–1993,” Diabetes Care, vol. 21, no. 7, pp. 1138–1145, 1998. View at Publisher · View at Google Scholar · View at Scopus
  5. B. Nguyen-Khoa, E. L. Goehring, W. Werther et al., “Hospitalized cardiovascular events in patients with diabetic macular edema,” BMC Ophthalmology, vol. 12, no. 1, 2012. View at Publisher · View at Google Scholar
  6. “Photocoagulation for diabetic macular edema. Early treatment diabetic retinopathy study report number 1. Early treatment diabetic retinopathy study group,” JAMA Ophtalmology, vol. 103, no. 12, pp. 1796–1806, 1985. View at Publisher · View at Google Scholar
  7. K. Maeshima, N. Utsugi-Sutoh, T. Otani, and S. Kishi, “Progressive enlargement of scattered photocoagulation scars in diabetic retinopathy,” Retina, vol. 24, no. 4, pp. 507–511, 2004. View at Publisher · View at Google Scholar · View at Scopus
  8. U. Schmidt-Erfurth, J. Garcia-Arumi, F. Bandello et al., “Guidelines for the management of diabetic macular edema by the European Society of Retina Specialists (EURETINA),” Ophthalmologica, vol. 237, no. 4, pp. 185–222, 2017. View at Publisher · View at Google Scholar · View at Scopus
  9. Q. D. Nguyen, D. M. Brown, D. M. Marcus et al., “Ranibizumab for diabetic macular edema: results from 2 phase iii randomized trials: RISE and RIDE,” Ophthalmology, vol. 119, no. 4, pp. 789–801, 2012. View at Publisher · View at Google Scholar · View at Scopus
  10. J.-F. Korobelnik, D. V. Do, U. Schmidt-Erfurth et al., “Intravitreal aflibercept for diabetic macular edema,” Ophthalmology, vol. 121, no. 11, pp. 2247–2254, 2014. View at Publisher · View at Google Scholar · View at Scopus
  11. K. Herland, J.-P. Akselsen, O. H. Skjønsberg, and L. Bjermer, “How representative are clinical study patients with asthma or COPD for a larger “real life” population of patients with obstructive lung disease?” Respiratory Medicine, vol. 99, no. 1, pp. 11–19, 2005. View at Publisher · View at Google Scholar · View at Scopus
  12. S. Saturni, F. Bellini, F. Braido et al., “Randomized controlled trials and real life studies. Approaches and methodologies: A clinical point of view.,” Pulmonary Pharmacology and Therapeutics, vol. 27, no. 2, pp. 129–138, 2014. View at Publisher · View at Google Scholar · View at Scopus
  13. M. A. Singer, P. U. Dugel, H. F. Fine, A. Capone, and J. Maltman, “Real-World Assessment of Dexamethasone Intravitreal Implant in DME: Findings of the Prospective, Multicenter REINFORCE Study,” Ophthalmic Surgery, Lasers & Imaging Retina, vol. 49, no. 6, pp. 425–435, 2018. View at Publisher · View at Google Scholar
  14. K. J. Blinder, P. U. Dugel, S. Chen et al., “Anti-VEGF treatment of diabetic macular edema in clinical practice: Effectiveness and patterns of use (ECHO study report 1),” Clinical Ophthalmology, vol. 11, pp. 393–401, 2017. View at Publisher · View at Google Scholar · View at Scopus
  15. S. Matsuda, T. Tam, R. P. Singh et al., “The impact of metabolic parameters on clinical response to VEGF inhibitors for diabetic macular edema,” Journal of Diabetes and its Complications, vol. 28, no. 2, pp. 166–170, 2014. View at Publisher · View at Google Scholar · View at Scopus
  16. C. P. Shah and J. S. Heier, “Aflibercept for diabetic macular edema in eyes previously treated with ranibizumab and/or bevacizumab may further improve macular thickness,” Ophthalmic Surgery, Lasers and Imaging Retina, vol. 47, no. 9, pp. 836–839, 2016. View at Publisher · View at Google Scholar · View at Scopus
  17. N. Shimizu, T. Oshitari, T. Tatsumi et al., “Comparisons of Efficacy of Intravitreal Aflibercept and Ranibizumab in Eyes with Diabetic Macular Edema,” BioMed Research International, vol. 2017, Article ID 1747108, 7 pages, 2017. View at Publisher · View at Google Scholar · View at Scopus
  18. T. Wecker, C. Ehlken, A. Bühler et al., “Five-year visual acuity outcomes and injection patterns in patients with pro-re-nata treatments for AMD, DME, RVO and myopic CNV,” British Journal of Ophthalmology, vol. 101, no. 3, pp. 353–359, 2017. View at Publisher · View at Google Scholar · View at Scopus
  19. G. Yiu, V. Manjunath, S. J. Chiu, S. Farsiu, and T. H. Mahmoud, “Effect of anti-vascular endothelial growth factor therapy on choroidal thickness in diabetic macular edema,” American Journal of Ophthalmology, vol. 158, no. 4, pp. 745–751.e2, 2014. View at Publisher · View at Google Scholar · View at Scopus
  20. B. Bahrami, T. Hong, M. Zhu, T. E. Schlub, and A. Chang, “Switching therapy from bevacizumab to aflibercept for the management of persistent diabetic macular edema,” Graefe's Archive for Clinical and Experimental Ophthalmology, vol. 255, no. 6, pp. 1133–1140, 2017. View at Publisher · View at Google Scholar · View at Scopus
  21. A. Herbaut, F. Fajnkuchen, L. Qu-Knafo, S. Nghiem-Buffet, B. Bodaghi, and A. Giocanti-Auregan, “Switching to Aflibercept in Diabetic Macular Edema Not Responding to Ranibizumab and/or Intravitreal Dexamethasone Implant,” Journal of Ophthalmology, vol. 2017, Article ID 8035013, 8 pages, 2017. View at Publisher · View at Google Scholar
  22. T. Kaiho, T. Oshitari, T. Tatsumi et al., “Efficacy of One-Year Treatment with Aflibercept for Diabetic Macular Edema with Practical Protocol,” BioMed Research International, vol. 2017, Article ID 7879691, 6 pages, 2017. View at Publisher · View at Google Scholar · View at Scopus
  23. K. A. Klein, T. S. Cleary, and E. Reichel, “Effect of intravitreal aflibercept on recalcitrant diabetic macular edema,” International Journal of Retina and Vitreous, vol. 3, no. 1, 2017. View at Publisher · View at Google Scholar
  24. S. Aksoy, G. Yilmaz, I. Akkoyun, and A. C. Yazici, “Comparison of intravitreal bevacizumab and triamcinolone acetonide theraphies for diffuse diabetic macular edema,” International Journal of Ophthalmology, vol. 8, no. 3, pp. 550–555, 2015. View at Google Scholar · View at Scopus
  25. D. S. Fong, T. Q. Luong, R. Contreras et al., “Treatment patterns and 2-year vision outcomes with bevacizumab in diabetic macular edema: an analysis from a large u.s. integrated health care system,” Retina, vol. 38, no. 9, pp. 1830–1838, 2018. View at Publisher · View at Google Scholar
  26. E. Güler, Y. Totan, and F. B. Güragaç, “Intravitreal bevacizumab and dexamethasone implant for treatment of chronic diabetic macular edema,” Cutaneous and Ocular Toxicology, vol. 36, no. 2, pp. 180–184, 2017. View at Publisher · View at Google Scholar · View at Scopus
  27. J. Hanhart, L. Tiosano, E. Averbukh, E. Banin, I. Hemo, and I. Chowers, “Fellow eye effect of unilateral intravitreal bevacizumab injection in eyes with diabetic macular edema,” Eye (Basingstoke), vol. 28, no. 6, pp. 646–653, 2014. View at Google Scholar · View at Scopus
  28. I. Koç, S. Kadaylfçllar, and B. Eldem, “Real-World Results of Intravitreal Ranibizumab, Bevacizumab, or Triamcinolone for Diabetic Macular Edema,” Ophthalmologica, vol. 239, no. 2-3, pp. 85–93, 2017. View at Publisher · View at Google Scholar · View at Scopus
  29. D. Kook, A. Wolf, T. Kreutzer et al., “Long-term effect of intravitreal bevacizumab (avastin) in patients with chronic diffuse diabetic macular edema,” Retina, vol. 28, no. 8, pp. 1053–1060, 2008. View at Publisher · View at Google Scholar · View at Scopus
  30. M. Riazi-Esfahani, H. Riazi-Esfahani, A. Ahmadraji et al., “Intravitreal bevacizumab alone or combined with 1 mg triamcinolone in diabetic macular edema: a randomized clinical trial,” International Ophthalmology, pp. 1–14, 2017. View at Google Scholar · View at Scopus
  31. C. Fechter, H. Frazier, W. B. Marcus, A. Farooq, H. Singh, and D. M. Marcus, “Ranibizumab 0.3 mg for persistent diabetic macular edema after recent, frequent, and chronic bevacizumab: The ROTATE trial,” Ophthalmic Surgery, Lasers and Imaging Retina, vol. 47, no. 11, pp. 1–18, 2016. View at Publisher · View at Google Scholar · View at Scopus
  32. E. Yuksel, S. Ozdek, N. Yuksel, and B. Hasanreisoglu, “Intravitreal bevacizumab treatment for refractory diabetic macular edema,” International Ophthalmology, vol. 33, no. 6, pp. 659–663, 2013. View at Publisher · View at Google Scholar · View at Scopus
  33. K. A. Solaiman, M. M. Diab, and S. A. Dabour, “Repeated intravitreal bevacizumab injection with and without macular grid photocoagulation for treatment of diffuse diabetic macular edema,” Retina, vol. 33, no. 8, pp. 1623–1629, 2013. View at Publisher · View at Google Scholar
  34. H. R. Cheema, A. A. Habash, and E. Al-Askar, “Improvement of visual acuity based on optical coherence tomography patterns following intravitreal bevacizumab treatment in patients with diabetic macular edema,” International Journal of Ophthalmology, vol. 7, no. 2, pp. 251–255, 2014. View at Google Scholar · View at Scopus
  35. B. Mushtaq, N. J. Crosby, A. T. Dimopoulos et al., “Effect of initial retinal thickness on outcome of intravitreal bevacizumab therapy for diabetic macular edema,” Clinical Ophthalmology, vol. 8, pp. 807–812, 2014. View at Publisher · View at Google Scholar · View at Scopus
  36. J. N. Crosson, L. Mason, and J. O. Mason, “The Role of Focal Laser in the Anti–Vascular Endothelial Growth Factor Era,” Ophthalmology and Eye Diseases, vol. 9, Article ID 1179172117738240, 2017. View at Publisher · View at Google Scholar
  37. I. Chatziralli, M. Santarelli, N. Patrao et al., “Identification of time point to best define sub-optimal response' following intravitreal ranibizumab therapy for diabetic macular edema based on real-life data,” Eye (Basingstoke), vol. 31, no. 11, pp. 1594–1599, 2017. View at Google Scholar · View at Scopus
  38. T. A. Ciulla, R. M. Hussain, L. M. Ciulla, B. Sink, and A. Harris, “Ranibizumab for diabetic macular edema refractory to multiple prior treatments,” Retina, vol. 36, no. 7, pp. 1292–1297, 2016. View at Publisher · View at Google Scholar · View at Scopus
  39. C. Egan, H. Zhu, A. Lee et al., “The United Kingdom Diabetic Retinopathy Electronic Medical Record Users Group, Report 1: Baseline characteristics and visual acuity outcomes in eyes treated with intravitreal injections of ranibizumab for diabetic macular oedema,” British Journal of Ophthalmology, vol. 101, no. 1, pp. 75–80, 2017. View at Publisher · View at Google Scholar · View at Scopus
  40. T. Granström, H. Forsman, A. Lindholm Olinder et al., “Patient-reported outcomes and visual acuity after 12 months of anti-VEGF-treatment for sight-threatening diabetic macular edema in a real world setting,” Diabetes Research and Clinical Practice, vol. 121, pp. 157–165, 2016. View at Publisher · View at Google Scholar · View at Scopus
  41. D. Hodzic-Hadzibegovic, B. A. Sander, T. J. Monberg, M. Larsen, and H. Lund-Andersen, “Diabetic macular oedema treated with intravitreal anti-vascular endothelial growth factor - 2-4 years follow-up of visual acuity and retinal thickness in 566 patients following Danish national guidelines,” Acta Ophthalmologica, 2017. View at Google Scholar · View at Scopus
  42. G. Katz, E. Moisseiev, D. Goldenberg et al., “Ranibizumab for persistent diabetic macular edema after bevacizumab treatment,” European Journal of Ophthalmology, vol. 27, no. 2, pp. 210–214, 2017. View at Publisher · View at Google Scholar · View at Scopus
  43. Y. Koyanagi, S. Yoshida, Y. Kobayashi et al., “Visual Outcomes Based on Early Response to Anti-Vascular Endothelial Growth Factor Treatment for Diabetic Macular Edema,” Ophthalmologica, vol. 239, no. 2-3, pp. 94–102, 2018. View at Publisher · View at Google Scholar · View at Scopus
  44. Y. Mori, T. Murakami, K. Suzuma et al., “Relation between macular morphology and treatment frequency during twelve months with ranibizumab for diabetic macular edema,” PLoS ONE, vol. 12, no. 4, 2017. View at Google Scholar · View at Scopus
  45. R. G. H. Wilke, R. P. Finger, and H. G. Sachs, “Real-life Data on the Treatment of Diabetic Macular Oedema in Germany,” Klin Monatsbl Augenheilkd, vol. 234, no. 12, pp. 1502–1507, 2017. View at Publisher · View at Google Scholar
  46. D. Akıncıoğlu, M. Küçükevcilioğlu, A. H. Durukan, S. Aykaş, Ö. Ayyıldız, and F. C. Erdurman, “Outcomes of intravitreal dexamethasone implant in the treatment of recalcitrant diabetic macular edema,” Türk Oftalmoloji Dergisi, vol. 47, no. 5, pp. 274–278, 2017. View at Publisher · View at Google Scholar · View at Scopus
  47. S. T. Alshahrani, R. Dolz-Marco, R. Gallego-Pinazo, M. Diaz-Llopis, and J. F. Arevalo, “Intravitreal dexamethasone implant for the treatment of refractory macular edema in retinal vascular diseases : Results of the KKESH International Collaborative Retina study group,” Retina, vol. 36, no. 1, pp. 131–136, 2016. View at Publisher · View at Google Scholar · View at Scopus
  48. P. Bansal, V. Gupta, A. Gupta, M. R. Dogra, and J. Ram, “Efficacy of Ozurdex implant in recalcitrant diabetic macular edema-a single-center experience,” International Ophthalmology, vol. 36, no. 2, pp. 207–216, 2016. View at Publisher · View at Google Scholar
  49. I. Chatziralli, P. Theodossiadis, E. Parikakis et al., “Dexamethasone Intravitreal Implant in Diabetic Macular Edema: Real-Life Data from a Prospective Study and Predictive Factors for Visual Outcome,” Diabetes Therapy, vol. 8, no. 6, pp. 1393–1404, 2017. View at Publisher · View at Google Scholar · View at Scopus
  50. J. Chhablani, P. Bansal, D. Veritti et al., “Dexamethasone implant in diabetic macular edema in real-life situations,” Eye (Basingstoke), vol. 30, no. 3, pp. 426–430, 2016. View at Google Scholar · View at Scopus
  51. M. V. Cicinelli, M. Cavalleri, L. Querques, A. Rabiolo, F. Bandello, and G. Querques, “Early response to ranibizumab predictive of functional outcome after dexamethasone for unresponsive diabetic macular oedema,” British Journal of Ophthalmology, vol. 101, no. 12, pp. 1689–1693, 2017. View at Publisher · View at Google Scholar · View at Scopus
  52. A. Degoumois, J. Akesbi, C. Laurens et al., “Efficacy of intravitreal dexamethasone implants in macular edema excluding venous occlusions: Results for a cohort of 80 patients,” Journal Français d'Ophtalmologie, vol. 38, no. 2, pp. 126–133, 2015. View at Publisher · View at Google Scholar · View at Scopus
  53. M. Dutra Medeiros, M. Postorino, R. Navarro, J. Garcia-Arumí, C. Mateo, and B. Corcóstegui, “Dexamethasone intravitreal implant for treatment of patients with persistent diabetic macular edema,” Ophthalmologica, vol. 231, no. 3, pp. 141–146, 2014. View at Publisher · View at Google Scholar · View at Scopus
  54. J. J. Escobar-Barranco, B. Pina-Marín, and M. Fernández-Bonet, “Dexamethasone implants in patients with naïve or refractory diffuse diabetic macular edema,” Ophthalmologica, vol. 233, pp. 176–185, 2015. View at Publisher · View at Google Scholar · View at Scopus
  55. E. Esen, S. Sizmaz, and N. Demircan, “Efficacy of dexamethasone intravitreal implant for the treatment of persistent diffuse diabetic macular edema,” International Ophthalmology, vol. 37, no. 1, 2017. View at Google Scholar · View at Scopus
  56. Iglicki et al., 1910-B0414 Poster Board Number and Communication ARVO & Euretina 2017.
  57. H. Kaldırım, S. Yazgan, K. Atalay, C. Gurez, and F. Savur, “Intravitreal dexamethasone implantation in patients with different morphological diabetic macular edema having insufficient response to ranibizumab,” Retina, 2017. View at Google Scholar
  58. V. Lozano López, M. Serrano García, C. Mantolán Sarmiento et al., “A cost-effectiveness study of dexamethasone implants in macular edema,” Archivos de la Sociedad Española de Oftalmología, vol. 90, no. 1, pp. 14–21, 2015. View at Publisher · View at Google Scholar · View at Scopus
  59. R. Mastropasqua, L. Toto, E. Borrelli et al., “Morphology and function over a one-year follow up period after intravitreal dexamethasone implant (Ozurdex) in patients with diabetic macular edema,” PLoS ONE, vol. 10, no. 12, 2015. View at Google Scholar · View at Scopus
  60. F. Matonti, S. Pommier, F. Meyer et al., “Long-term efficacy and safety of intravitreal dexamethasone implant for the treatment of diabetic macular edema,” European Journal of Ophthalmology, vol. 26, no. 5, pp. 454–459, 2016. View at Publisher · View at Google Scholar · View at Scopus
  61. B. G. Moon, J. Y. Lee, H. G. Yu et al., “Efficacy and Safety of a Dexamethasone Implant in Patients with Diabetic Macular Edema at Tertiary Centers in Korea,” Journal of Ophthalmology, vol. 2016, Article ID 9810270, 9 pages, 2016. View at Publisher · View at Google Scholar
  62. S. Guigou, S. Pommier, and F. Meyer, “Efficacy and safety of intravitreal dexamethasone implant in patients with diabetic macular edema,” Ophthalmologica, vol. 233, no. 3-4, pp. 169–175, 2015. View at Publisher · View at Google Scholar
  63. I. Aknin and L. Melki, “Longitudinal study of sustained-release dexamethasone intravitreal implant in patients with diabetic macular edema,” Ophthalmologica, vol. 235, no. 4, pp. 187-188, 2016. View at Publisher · View at Google Scholar · View at Scopus
  64. E. Pacella, A. R. Vestri, R. Muscella et al., “Preliminary results of an intravitreal dexamethasone implant (Ozurdex®) in patients with persistent diabetic macular edema,” Clinical Ophthalmology, vol. 7, pp. 1423–1428, 2013. View at Google Scholar · View at Scopus
  65. A. Pareja-Ríos, P. Ruiz-De la Fuente-Rodríguez, S. Bonaque-González, M. López-Gálvez, V. Lozano-López, and P. Romero-Aroca, “Intravitreal dexamethasone implants for diabetic macular edema,” International Journal of Ophthalmology, vol. 11, no. 1, pp. 77–82, 2018. View at Google Scholar · View at Scopus
  66. D. Bellocq, J. Akesbi, F. Matonti et al., “The Pattern of Recurrence in Diabetic Macular Edema Treated by Dexamethasone Implant: The PREDIAMEX Study,” Ophthalmology Retina, vol. 2, no. 6, pp. 567–573, 2018. View at Publisher · View at Google Scholar
  67. A. Malcles, C. Dot, N. Voirin et al., “Real-life study in diabetic macular edema treated with dexamethasone implant: The reldex study,” Retina, vol. 37, no. 4, pp. 753–760, 2017. View at Publisher · View at Google Scholar · View at Scopus
  68. R. Sacconi, M. B. Parodi, S. Casati, R. Lattanzio, G. Marchini, and F. Bandello, “Dexamethasone Implants in Diabetic Macular Edema Patients with High Visual Acuity,” Ophthalmic Research, vol. 58, no. 3, pp. 125–130, 2017. View at Publisher · View at Google Scholar · View at Scopus
  69. Y. Totan, E. Güler, and F. B. Gürağaç, “Dexamethasone intravitreal implant for chronic diabetic macular edema resistant to intravitreal bevacizumab treatment,” Current Eye Research, vol. 41, no. 1, pp. 107–113, 2016. View at Publisher · View at Google Scholar · View at Scopus
  70. E. Unsal, K. Eltutar, P. Sultan, S. O. Erkul, and O. A. Osmanbasoglu, “Efficacy and Safety of Intravitreal Dexamethasone Implants for Treatment of Refractory Diabetic Macular Edema,” Korean Journal of Ophthalmology, vol. 31, no. 2, p. 115, 2017. View at Publisher · View at Google Scholar
  71. O. E. Yucel, E. Can, H. E. Ozturk, H. Birinci, and Y. Sullu, “Dexamethasone Implant in Chronic Diabetic Macular Edema Resistant to Intravitreal Ranibizumab Treatment,” Ophthalmic Research, vol. 57, no. 3, pp. 161–165, 2017. View at Publisher · View at Google Scholar · View at Scopus
  72. I. Zhioua, O. Semoun, F. Lalloum, and E. H. Souied, “Intravitreal dexamethasone implant in patients with ranibizumab persistent diabetic macular edema,” Retina, vol. 35, no. 7, pp. 1429–1435, 2015. View at Publisher · View at Google Scholar · View at Scopus
  73. M. Arıkan Yorgun, Y. Toklu, M. Mutlu, B. S. Uysal, and H. B. Çakmak, “Efficacy of single-dose dexamethasone implantation in patients with persistent diabetic macular edema,” International Ophthalmology, vol. 36, no. 4, pp. 531–539, 2016. View at Publisher · View at Google Scholar · View at Scopus
  74. M. Scaramuzzi, G. Querques, C. L. Spina, R. Lattanzio, and F. Bandello, “Repeated intravitreal dexamethasone implant (Ozurdex) for diabetic macular edema,” Retina, vol. 35, no. 6, pp. 1216–1222, 2015. View at Publisher · View at Google Scholar · View at Scopus
  75. M. J. Elman, L. P. Aiello, and R. W. Beck, “Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema,” Ophthalmology, vol. 117, no. 6, pp. 1064.e35–1077.e35, 2010. View at Publisher · View at Google Scholar · View at Scopus
  76. M. Michaelides, A. Kaines, R. D. Hamilton et al., “A prospective randomized trial of intravitreal bevacizumab or laser therapy in the management of diabetic macular edema (BOLT study) 12-month data: report 2,” Ophthalmology, vol. 117, no. 6, pp. 1078–1086, 2010. View at Publisher · View at Google Scholar · View at Scopus
  77. P. Massin, F. Bandello, J. G. Garweg et al., “Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE study): a 12-month, randomized, controlled, double-masked, multicenter phase II study,” Diabetes Care, vol. 33, no. 11, pp. 2399–2405, 2010. View at Publisher · View at Google Scholar · View at Scopus
  78. T. Ishibashi, X. Li, A. Koh et al., “The REVEAL study: ranibizumab monotherapy or combined with laser versus laser monotherapy in asian patients with diabetic macular edema,” Ophthalmology, vol. 122, no. 7, pp. 1402–1415, 2015. View at Google Scholar
  79. P. Mitchell, F. Bandello, U. Schmidt-Erfurth et al., “The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema,” Ophthalmology, vol. 118, no. 4, pp. 615–625, 2011. View at Publisher · View at Google Scholar · View at Scopus
  80. I. Pearce, S. Banerjee, and B. J. L. Burton, “Ranibizumab 0.5 mg for diabetic macular edema with bimonthly monitoring after a phase ofinitial treatment: 18-month, multicenter, phase IIIB RELIGHT study,” Opthalmology, vol. 122, no. 9, pp. 1811–1819, 2015. View at Publisher · View at Google Scholar
  81. The Diabetic Retinopathy Clinical Research Network, J. A. Wells, A. R. Glassman et al., “Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema,” The New England Journal of Medicine, vol. 372, pp. 1193–1203, 2015. View at Publisher · View at Google Scholar
  82. D. S. Boyer, Y. H. Yoon, R. Belfort Jr. et al., “Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema,” Ophthalmology, vol. 121, pp. 1904–1914, 2014. View at Publisher · View at Google Scholar · View at Scopus
  83. D. G. Callanan, S. Gupta, D. S. Boyer et al., “Dexamethasone intravitreal implant in combination with laser photocoagulation for the treatment of diffuse diabetic macular edema,” Ophthalmology, vol. 120, no. 9, pp. 1843–1851, 2013. View at Publisher · View at Google Scholar · View at Scopus
  84. D. G. Callanan, A. Loewenstein, S. S. Patel et al., “A multicenter, 12-month randomized study comparing dexamethasone intravitreal implant with ranibizumab in patients with diabetic macular edema,” Graefe's Archive for Clinical and Experimental Ophthalmology, vol. 255, no. 3, pp. 463–473, 2017. View at Publisher · View at Google Scholar · View at Scopus
  85. M. C. Gillies, L. L. Lim, A. Campain et al., “A randomized clinical trial of intravitreal bevacizumab versus intravitreal dexamethasone for diabetic macular edema: The BEVORDEX study,” Ophthalmology, vol. 121, no. 12, pp. 2473–2481, 2014. View at Publisher · View at Google Scholar · View at Scopus
  86. R. Turner, R. Holman, I. Stratton et al., “Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38,” British Medical Journal, vol. 317, no. 7160, pp. 703–713, 1998. View at Publisher · View at Google Scholar · View at Scopus
  87. V. H. Gonzalez, J. Campbell, N. M. Holekamp et al., “Early and long-term responses to anti-vascular endothelial growth factor therapy in diabetic macular edema: analysis of protocol i data,” American Journal of Ophthalmology, vol. 172, pp. 72–79, 2016. View at Google Scholar
  88. U. Schmidt-Erfurth, G. E. Lang, F. G. Holz et al., “Three-year outcomes of individualized ranibizumab treatment in patients with diabetic macular edema: the RESTORE extension study,” Ophthalmology, vol. 121, no. 5, pp. 1045–1053, 2014. View at Publisher · View at Google Scholar · View at Scopus
  89. CATT Research Group, D. F. Martin, M. G. Maguire et al., “Ranibizumab and bevacizumab for neovascular age-related macular degeneration,” The New England Journal of Medicine, vol. 64, no. 20, pp. 1897–1908, 2011. View at Publisher · View at Google Scholar
  90. IVAN Study Investigators, U. Chakravarthy, S. P. Harding et al., “Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial,” Ophthalmology, vol. 119, no. 7, pp. 1399–1411, 2012. View at Publisher · View at Google Scholar
  91. B. G. Busbee, A. C. Ho, D. M. Brown et al., “Twelve-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration,” Ophthalmology, vol. 120, no. 5, pp. 1046–1056, 2013. View at Publisher · View at Google Scholar
  92. P. J. Rosenfeld, D. M. Brown, J. S. Heier et al., “Ranibizumab for neovascular age-related macular degeneration,” The New England Journal of Medicine, vol. 355, no. 14, pp. 1419–1431, 2006. View at Publisher · View at Google Scholar · View at Scopus
  93. D. M. Brown, P. A. Campochiaro, R. B. Bhisitkul et al., “Sustained benefits from ranibizumab for macular edema following branch retinal vein occlusion: 12-month outcomes of a phase III study,” Ophthalmology, vol. 118, no. 8, pp. 1594–1602, 2011. View at Publisher · View at Google Scholar · View at Scopus
  94. P. A. Campochiaro, D. M. Brown, C. C. Awh et al., “Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: Twelve-month outcomes of a phase III study,” Ophthalmology, vol. 118, no. 10, pp. 2041–2049, 2011. View at Publisher · View at Google Scholar · View at Scopus
  95. F. Audren, A. Lecleire-Collet, A. Erginay et al., “Intravitreal Triamcinolone Acetonide for Diffuse Diabetic Macular Edema: Phase 2 Trial Comparing 4 mg vs 2 mg,” American Journal of Ophthalmology, vol. 142, no. 5, pp. 794–e8, 2006. View at Publisher · View at Google Scholar · View at Scopus
  96. A. Lambiase, S. Abdolrahimzadeh, and S. M. Recupero, “An update on intravitreal implants in use for eye disorders,” Drugs of Today, vol. 50, no. 3, pp. 239–249, 2014. View at Publisher · View at Google Scholar · View at Scopus
  97. M. W. Stewart, “Critical appraisal of ranibizumab in the treatment of diabetic macular edema,” Clinical Ophthalmology, vol. 7, pp. 1257–1267, 2013. View at Publisher · View at Google Scholar · View at Scopus
  98. Y. Zhou, M. Zhou, S. Xia, Q. Jing, and L. Gao, “Sustained Elevation of Intraocular Pressure Associated with Intravitreal Administration of Anti-vascular Endothelial Growth Factor: A Systematic Review and Meta-Analysis,” Scientific Reports, vol. 6, no. 1, 2016. View at Publisher · View at Google Scholar
  99. S. B. Bressler, T. Almukhtar, A. Bhorade et al., “Repeated intravitreous ranibizumab injections for diabetic macular edema and the risk of sustained elevation of intraocular pressure or the need for ocular hypotensive treatment,” JAMA Ophthalmology, vol. 133, no. 5, pp. 589–597, 2015. View at Publisher · View at Google Scholar
  100. A. Malclès, C. Dot, N. Voirin et al., “SAFETY of INTRAVITREAL DEXAMETHASONE IMPLANT (OZURDEX): The SAFODEX study. Incidence and Risk Factors of Ocular Hypertension,” Retina, vol. 37, no. 7, pp. 1352–1359, 2017. View at Publisher · View at Google Scholar · View at Scopus